Acelrx Pharmaceuticals Inc EBITDA margin
What is the EBITDA margin of Acelrx Pharmaceuticals Inc?
The EBITDA margin of Acelrx Pharmaceuticals Inc is -1,019.54%
What is the definition of EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin of companies in the Health Care sector on NASDAQ compared to Acelrx Pharmaceuticals Inc
What does Acelrx Pharmaceuticals Inc do?
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Companies with ebitda margin similar to Acelrx Pharmaceuticals Inc
- Yojee has EBITDA margin of -1,037.74%
- Mobi724 Global Solutions has EBITDA margin of -1,030.45%
- EVR plc has EBITDA margin of -1,028.22%
- Geomega Resources has EBITDA margin of -1,026.97%
- STARAMBA SE has EBITDA margin of -1,025.89%
- Spruce Ridge Resources has EBITDA margin of -1,021.41%
- Acelrx Pharmaceuticals Inc has EBITDA margin of -1,019.54%
- Empire Resources has EBITDA margin of -1,015.47%
- Angel Wing Metals has EBITDA margin of -1,015.47%
- Pacifico Minerals has EBITDA margin of -1,013.94%
- Adrabbit has EBITDA margin of -1,007.72%
- Oventus Medical has EBITDA margin of -1,005.03%
- Wins Finance has EBITDA margin of -997.38%